Form 4: United Therapeutics EVP Paul Mahon Executes Share Tracking Award Exercises

Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking award exercises on October 3 and October 17, 2024, according to a Form 4 filing.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corporation, reported changes in beneficial ownership via a Form 4 filing.
• The transactions involved the exercise of share tracking awards (STAPs) on October 3 and October 17, 2024.
• Each exercise involved 7,700 share tracking awards at a price of $163.3.
• The exercises were conducted pursuant to a pre-arranged 10b5-1 plan entered into on June 20, 2024.
• The October 3, 2024 STAP exercise was reported late due to an administrative error.
• Following the reported transactions, Mahon beneficially owns 36,710 shares of common stock directly and 68,150 share tracking awards.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports routine transactions related to executive compensation. The late reporting of one transaction is a minor negative, but overall, the information is factual and doesn't indicate significant positive or negative implications.

Negatives

• The October 3, 2024 STAP exercise was reported late due to an administrative error.

Industry Context

This filing reflects routine executive compensation practices within publicly traded companies, where stock-based awards are used to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock appreciation rights (SARs) are a common form of equity compensation, similar to stock options but settled in cash or stock equal to the appreciation in the stock price.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation plans for their executives.
• The use of a 10b5-1 trading plan is a standard practice to allow insiders to trade company stock without concerns about insider trading, provided the plan is established when they do not possess material non-public information.

Stakeholder Impact

• The exercise of share tracking awards has a minimal impact on shareholders, as these awards are cash-settled and non-dilutive.
• The transactions reflect ongoing compensation for the executive, which is of interest to shareholders.

Key Dates